ERBB2 and gastric cancer: The ToGA study developed a new set of IHC scoring criteria based on the study by Hofmann et al. [19] and found HER2-positive (defined as IHC 3+ or IHC 2+/FISH+) tumors in 16% of metastatic GC cases.